BR112012015967B1 - uso de compostos de fórmula geral (i) e composição farmacêutica - Google Patents

uso de compostos de fórmula geral (i) e composição farmacêutica Download PDF

Info

Publication number
BR112012015967B1
BR112012015967B1 BR112012015967A BR112012015967A BR112012015967B1 BR 112012015967 B1 BR112012015967 B1 BR 112012015967B1 BR 112012015967 A BR112012015967 A BR 112012015967A BR 112012015967 A BR112012015967 A BR 112012015967A BR 112012015967 B1 BR112012015967 B1 BR 112012015967B1
Authority
BR
Brazil
Prior art keywords
carboline
cech
cec
methyl
compound
Prior art date
Application number
BR112012015967A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012015967A2 (pt
Inventor
Rommelspacher Hans
Original Assignee
Audiocure Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Audiocure Pharma Gmbh filed Critical Audiocure Pharma Gmbh
Publication of BR112012015967A2 publication Critical patent/BR112012015967A2/pt
Publication of BR112012015967B1 publication Critical patent/BR112012015967B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012015967A 2009-12-28 2010-12-28 uso de compostos de fórmula geral (i) e composição farmacêutica BR112012015967B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009060811 2009-12-28
US28239510P 2010-02-02 2010-02-02
PCT/DE2010/001530 WO2011079841A1 (de) 2009-12-28 2010-12-28 Beta-carboline zur behandlung von hörschäden und schwindel

Publications (2)

Publication Number Publication Date
BR112012015967A2 BR112012015967A2 (pt) 2016-04-19
BR112012015967B1 true BR112012015967B1 (pt) 2019-08-27

Family

ID=44246908

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012015967A BR112012015967B1 (pt) 2009-12-28 2010-12-28 uso de compostos de fórmula geral (i) e composição farmacêutica

Country Status (17)

Country Link
US (1) US9107914B2 (enExample)
EP (1) EP2519238B1 (enExample)
JP (1) JP5627705B2 (enExample)
KR (1) KR20120098855A (enExample)
CN (1) CN102844029A (enExample)
AU (1) AU2010338669A1 (enExample)
BR (1) BR112012015967B1 (enExample)
CA (1) CA2785233C (enExample)
DE (1) DE112010005017A5 (enExample)
IL (1) IL220661A (enExample)
IN (1) IN2012DN05066A (enExample)
MX (1) MX2012007678A (enExample)
NZ (1) NZ600478A (enExample)
RU (1) RU2012132429A (enExample)
SG (1) SG181599A1 (enExample)
WO (1) WO2011079841A1 (enExample)
ZA (1) ZA201204476B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113416187B (zh) * 2013-03-14 2024-07-19 奥斯菲治疗有限公司 促进骨生长的烷基胺骆驼蓬碱衍生物
CA2905842C (en) 2013-03-14 2023-02-21 The Brigham And Women's Hospital, Inc. Compositions and methods for epithelial stem cell expansion comprising a wnt agonist and a histone deacetylase inhibitor
EP2853533A1 (de) * 2013-09-29 2015-04-01 Audiocure Pharma GmbH 6-Fluor-9-methyl-ß-carbolin
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
US11021687B2 (en) 2016-01-08 2021-06-01 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
EP3321264A1 (en) * 2016-11-14 2018-05-16 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways
US11066419B2 (en) 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
KR20210075971A (ko) 2018-08-14 2021-06-23 오스테오큐씨 인코포레이티드 플루오로 β-카볼린 화합물
US10947236B2 (en) 2018-08-14 2021-03-16 Osteoqc Inc. Pyrrolo-dipyridine compounds
EP3837351A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
CN113195707A (zh) 2018-08-17 2021-07-30 频率治疗公司 用于通过上调jag-1来生成毛细胞的组合物和方法
JP2022500407A (ja) * 2018-09-12 2022-01-04 ハフ イアー インスティテュート 人工内耳手術に伴う難聴の治療方法
EP3772515A1 (en) 2019-08-09 2021-02-10 Audiocure Pharma GmbH Stable polymorphic form of 6-fluoro-9-methyl-9h-ss-carboline and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3240514A1 (de) 1982-10-29 1984-05-03 Schering AG, 1000 Berlin und 4709 Bergkamen Ss-carboline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US20040038970A1 (en) * 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
DE69904595T2 (de) * 1998-06-12 2003-11-27 Societe De Conseils De Recherches Et D'applications Scientifiques S.A., Paris Betacarbolinverbindungen
US20050101623A1 (en) * 2003-07-23 2005-05-12 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
DE102007009264A1 (de) * 2007-02-26 2008-08-28 Ellneuroxx Ltd. 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen

Also Published As

Publication number Publication date
AU2010338669A1 (en) 2012-06-21
RU2012132429A (ru) 2014-02-10
MX2012007678A (es) 2012-09-12
WO2011079841A1 (de) 2011-07-07
JP5627705B2 (ja) 2014-11-19
US20130028958A1 (en) 2013-01-31
CN102844029A (zh) 2012-12-26
IL220661A (en) 2016-03-31
IL220661A0 (en) 2012-08-30
JP2013515752A (ja) 2013-05-09
CA2785233A1 (en) 2011-06-07
EP2519238B1 (de) 2014-08-13
BR112012015967A2 (pt) 2016-04-19
NZ600478A (en) 2013-10-25
CA2785233C (en) 2018-10-09
DE112010005017A5 (de) 2012-10-04
SG181599A1 (en) 2012-07-30
EP2519238A1 (de) 2012-11-07
KR20120098855A (ko) 2012-09-05
ZA201204476B (en) 2014-01-29
IN2012DN05066A (enExample) 2015-10-09
US9107914B2 (en) 2015-08-18

Similar Documents

Publication Publication Date Title
BR112012015967B1 (pt) uso de compostos de fórmula geral (i) e composição farmacêutica
ES2248950T3 (es) Utilizacion de cuatro derivados de k-252a.
US20100144858A1 (en) Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
WO2010133742A1 (es) Uso de derivados de quinazolinas en enfermedades neurodegenerativas
EP3445362B1 (en) Composition and method for treating metabolic disorders
DK2941429T3 (en) Fluoro-9-methyl-beta-carboline
EP4340940A1 (en) Compositions and methods of tissue regeneration therapy
ES2447834T3 (es) Composición y método para tratar o prevenir la fibrosis del músculo esquelético
JP2000309545A (ja) 愛玩動物の年齢関連行動障害治療方法および治療用組成物
Yamamoto et al. Effects of locus coeruleus stimulation on muricide in olfactory bulbectomized and raphe lesioned rats
ES2481790T3 (es) Profármacos de [4[4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(1H-pirrolo-piridin-il)-metanonas y síntesis de los mismos
WO2021214950A1 (ja) 精神疾患を治療、予防又は管理するための医薬組成物
WO2009110526A1 (ja) 3’,5-ジ-2-プロペニル-(1,1’-ビフェニル)-2,4’-ジオールを有効成分として含有する視神経障害の予防又は治療剤
CA2376199A1 (en) Use of verapamil and verapamil derivatives for producing medicaments with an inhibiting effect on .beta.-glucuronidase in human tissue
US20110319463A1 (en) Preventive or therapeutic agents for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivatives or salts thereof as active ingredients
HK40039902A (en) Compounds for treatment of cardiac arrhythmias and heart failure
JP2008100948A (ja) 硫化水素および/または硫化水素塩を含有する神経細胞分化促進剤およびその方法
JP2010526830A (ja) 黒色腫の処置のためのhdac阻害剤の使用

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/12/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/12/2010, OBSERVADAS AS CONDICOES LEGAIS